Literature DB >> 646327

Combinations of cytotoxic agents that have less than expected toxicity on normal tissues in mice.

J L Millar, T J McElwain.   

Abstract

A pretreatment dose of cyclophosphamide reduced lethality caused by high doses of busulphan or cyclophosphamide. In the case of cyclophosphamide given prior to busulphan, increased survival could be attributed to greater regeneration of haemopoietic stem cells in animals that received the combined dose compared with those that received busulphan alone. The mechanism by which cyclophosphamide pretreatment increased the animals' tolerance to a large dose of cyclophosphamide has not yet been elucidated. However, the urothelium in mice given the combined treatment was much less damaged than the urothelium in mice given the large dose alone, and its a known that bladder damage is a major feature of toxicity in patients given high-dose cyclophosphamide. This sparing combination exerted its expected toxicity on Lewis lung tumours, however, and so provided a useful differential effect against tumour tissue.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 646327     DOI: 10.1159/000401490

Source DB:  PubMed          Journal:  Antibiot Chemother (1971)        ISSN: 0066-4758


  10 in total

1.  The effect of pretreatment with thio-TEPA and cytosine arabinoside on megakaryocytopoiesis in rats given a sublethal dose of thio-TEPA.

Authors:  G Tanum; A Sønstevold; A Engeset
Journal:  Blut       Date:  1987-01

2.  Metabolism of high doses of cyclophosphamide.

Authors:  R A Milsted; M Jarman
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.

Authors:  A Zimber; K Perk; I Livnat
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

4.  Combined modality therapy: clinical and laboratory aspects.

Authors: 
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

5.  British Association for Cancer Research 22nd Annual general meeting. 13-15 April 1981. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

6.  Transition from laboratory to clinic in cancer treatment. Abstracts of symposium papers.

Authors: 
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

7.  Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.

Authors:  J L Millar; B N Hudspith; T J McElwain; T A Phelps
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

8.  Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.

Authors:  B D Evans; I E Smith; R D Clutterbuck; J L Millar
Journal:  Br J Cancer       Date:  1984-01       Impact factor: 7.640

9.  Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.

Authors:  J A Maitland; B C Millar; J B Bell; A Montes; J Treleaven; M E Gore; T J McElwain
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

10.  High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice.

Authors:  B D Evans; I E Smith; J L Millar
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.